Drugmaker Johnson & Johnson has halted manufacturing of its single-dose COVID-19 vaccine, based on a New York Instances report.

The pharmaceutical firm final 12 months quietly shut down manufacturing at a plant in Leiden, Netherlands, which was the one facility the place usable doses of the vaccine had been manufactured, catching a few of its clients off guard, together with growing nations that desire the single-dose J&J drug over two-dose options, the report states. 

Johnson & Johnson has as a substitute been utilizing the plant to work on an experimental and probably extra worthwhile drug that might shield in opposition to an unrelated respiratory virus, based on the report. 

The plant is anticipated to renew manufacturing of the COVID-19 vaccine, however it’s unclear when. 

J&J didn’t touch upon the plant closure reviews, however mentioned in a press release to CBS Information “we at present have thousands and thousands of doses of our COVID-19 vaccine in stock” and “we proceed to satisfy our contractual obligations … [to] the African Union.” 

Vaccine of alternative for poorer international locations

The J&J vaccine, known as the Janssen COVID-19 vaccine, made by Janssen Biotech, a subsidiary of Johnson & Johnson, is the vaccine of alternative for poorer international locations which are relying on the drugmaker to assist them battle the pandemic. 

COVID deaths nonetheless rising as instances drop


Wealthier nations just like the U.S. have favored pictures from Moderna and Pfizer, as a result of the 2 look like simpler in opposition to COVID-19 variants like Omicron, and since the Janssen vaccine has, up to now, been linked to uncommon however probably life-threatening blood clots. 

Provided that just one dose of the J&J vaccine is required, although, it is cheaper than its double-dose counterparts and in addition simpler to ship, making it standard in lower-income international locations. 


Leave a Reply

Your email address will not be published.